Allergan’s GI business grows by 8.2% in Q3 & more — 3 GI company key notes

Here are three updates on gastroenterology and endoscopy companies.

Advertisement

Despite falling revenues, Madison, N.J.-based Allergan’s gastroenterology franchise grew by 8.2 percent in the third quarter.

Cambridge, Mass.-based Idera Pharmaceuticals and Bermuda-based Vivelix Pharmaceuticals entered into an exclusive license and collaboration agreement.

Genetic Technologies and Australia-based University of Melbourne have entered a license agreement to develop a new colorectal cancer risk assessment test.

More articles on gastroenterology and endoscopy:
Do financial incentives promote patient adherence to CRC screening? 5 study insights
Genetic Technologies, University of Melbourne collaborate on CRC risk assessment tool: 3 notes
Outreach to cirrhosis patients increases likelihood of liver cancer screening: 3 study insights

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.